An anonymous director reports

ZYUS LIFE SCIENCES ANNOUNCES CLOSING OF DEBT FINANCING

Zyus Life Sciences Corp. closed a debt financing on March 5, 2026, pursuant to which it issued an unsecured promissory note in the principal amount of $500,000 to an arm's-length third party lender.

The unsecured note bears interest at a rate of 12 per cent per annum from the date of issuance, calculated on a simple basis, and matures on Aug. 5, 2026. Interest on the unsecured note is payable at maturity. The unsecured note is not convertible to equity, and the company may prepay this unsecured note, including accrued interest, at any time without penalty or premium.

The company intends to use proceeds from the debt financing for general working capital purposes.

The unsecured note pursuant to the debt financing is subject to notice requirement under the rules of the TSX Venture Exchange.

About Zyus Life Sciences Corp.

Zyus is a clinical-stage life science company focused on the development and commercialization of novel non-opioid pharmaceutical drug candidates for pain management. Through rigorous scientific exploration and clinical research, Zyus aims to secure intellectual property protection, safeguarding its innovative therapies and bolstering shareholder value. Zyus's unwavering commitment extends to obtaining regulatory approval of non-opioid-based pharmaceutical solutions in pursuit of transformational impact on patients' lives.

We seek Safe Harbor.